North America Intravenous Iron Drugs Market Size & Outlook
Related Markets
North America intravenous iron drugs market highlights
- The North America intravenous iron drugs market generated a revenue of USD 1,664.2 million in 2024.
- The market is expected to grow at a CAGR of 7.7% from 2025 to 2030.
- In terms of segment, ferric carboxymaltose was the largest revenue generating product in 2024.
- Ferric Carboxymaltose is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 1,664.2 million |
| Market revenue in 2030 | USD 2,606.3 million |
| Growth rate | 7.7% (CAGR from 2025 to 2030) |
| Largest segment | Ferric carboxymaltose |
| Fastest growing segment | Ferric Carboxymaltose |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 50.4% of the global intravenous iron drugs market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 819.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Rockwell Medical Inc | View profile | 237 | 30142 S. Wixom Road, Wixom, MI, United States, 48393 | https://www.rockwellmed.com |
| COSMOS Pharmaceutical Corp | View profile | 24188 | 4 floor,10th first Fukuoka S Building Museum, Hakataekihigashi 2-chome,, Fukuoka, Japan, 812-0013 | http://www.cosmospc.co.jp |
| Civitas Resources Inc Ordinary Shares | View profile | 516 | 555 17th Street, Suite 3700, Denver, CO, United States, 80202 | https://www.civitasresources.com |
| Zydus Lifesciences | View profile | 10001+ | Ahmedabad, Gujarat, India, Asia | https://zyduslife.com/ |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
North America intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 47.01% in 2024. Horizon Databook has segmented the North America intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
In 2022, North America held a substantial share of the Intravenous (IV) iron drugs market, primarily due to the increasing approvals and launch of new IV drugs in the U.S. For instance, in December 2021, American Regent, Inc. and Daiichi Sankyo, Inc. disclosed that the U.S. FDA granted approval for Injective for pediatric patients with Iron Deficiency Anemia (IDA) who are insensitive to oral iron or who have exhibited an inadequate response to receiving oral iron.
These patients must be at least a year old. The suggested dosage for patients weighing below 50 kg is two intravenous doses of Injective 15 mg/kg body weight at least 7 days apart for each course. North America held a dominant share of the market, which can be attributed to increasing prevalence of cancer, Chronic Kidney Disease (CKD), and gastrointestinal disorders in the region.
For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected to be diagnosed in 2023. Furthermore, increasing awareness about women’s health and rising prevalence of celiac diseases are also some of the other factors driving the regional market growth.
Reasons to subscribe to North America intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America intravenous iron drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America intravenous iron drugs market size, by country, 2018-2030 (US$M)
North America Intravenous Iron Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
